Epithelioma Treatment Market – By Type, By Drug Class, By Distribution Channel – Global Forecast, 2025 to 2034

Epithelioma Treatment Market Size

The global epithelioma treatment market size was valued at around USD 5.2 billion in 2024. The market is expected to reach USD 11.5 billion by 2034, growing at 9.4% CAGR from 2025 to 2034. Treatment of epithelioma involves various medical and therapeutic approaches aimed at tumors of epithelial tissues, which are the tissues covering the body's surface cavities and organs.
 

These tumors may be cancerous such as basal cell carcinoma and squamous cell carcinoma, or non-cancerous. The objective of treatment includes the total or partial removal of neoplasm, restricting its formation, and the destruction of harmful effects.

The focus on the epithelial tumor treatment market is increasing due to the growing number of skin cancer cases, continuous advancements in treatment options, higher public focus on early detection, and governmental support. For instance, the American Cancer Society reports that an estimated 5.4 million cases of basal and squamous skin cancer are diagnosed annually in the U.S., which poses a significant burden to the healthcare.
 

Moreover, deaths caused by these cancers can range from 2,000 to 8,000 annually, which is mainly attributed to squamous cell carcinoma. The increase in these patients is fueling the treatment market by boosting the demand for effective treatment options and funding for R&D endeavors, which has a positive impact on the patients.
 

Moreover, the market is projected to expand because of considerable improvements in medical technologies and the introduction of new therapeutic solutions. Treatment advancements have enabled the professionals to effectively manage skin cancer of their patients. In addition, regulatory bodies are providing approvals for skin cancer therapies, further supporting the market progression. For instance, the anti-PD-1 monoclonal antibody pembrolizumab (KEYTRUDA) was issued an FDA immunotherapy approval in June 2020 for metastatic or recurrent cutaneous squamous cell carcinoma, which expanded the available options for patients. These improvements are expected to enhance the market in the near future.
 

Epithelioma Treatment Market Trends

• The treatment of epithelioma is witnessing a surge in the adoption of combination therapies. These strategies incorporate the integration of immunotherapy with either targeted therapy or radiation treatment in order to increase the effectiveness of treatment while overcoming the limitations associated with the single-agent therapies. Combination treatment therapy is expected to improve overall treatment outcomes while reducing the likelihood of developing resistance, thus further propelling the market expansion as healthcare practitioners look for better solutions for complicated cases.
   
• Furthermore, there is an increasing support from the U.S. FDA and other agencies for the accelerated approval of novel skin cancer treatments. There is an increasing use of breakthrough therapy designations and fast track approvals, which facilitate quicker access for patients to new treatment options.
   
• For instance, in March 2024, a global oncology company, BeiGene, Ltd., announced the approval by the U.S. FDA for TEVIMBRA (tislelizumab-jsgr) to be used as a monotherapy for adults suffering from unresectable or metastatic esophageal squamous cell carcinoma (ESCC). This regulatory support is leading to skin cancer therapies being developed and marketed at a much faster rate.
   

Epithelioma Treatment Market Analysis

Based on type, the market is segmented into basal cell carcinoma, squamous cell carcinoma, and other types. The basal cell carcinoma segment dominated the market with the largest revenue of USD 3.5 billion in 2024.
 

• Basal cell carcinoma segment is a major market share holding segment due to basal cell carcinoma being the most common skin cancer type across the globe. In May 2022, a report from the National Library of Medicine highlighted that basal cell carcinoma accounts for 80-85% of non-melanoma skin cancer, marking it as a sizable public health issue.
   
• The skin cancer growth rate in the world is increasing partially due to higher environmental UV exposure and changing lifestyles which has increased the effort towards developing and improving therapies for BCC, indicating a greater need for basal cell carcinoma treatment.
   
• Furthermore, there is an increased awareness about early diagnosis, which has further contributed to the segment’s growth.

Based on drug class, the epithelioma treatment market is segmented into hedgehog pathway inhibitors, immune checkpoint inhibitors, chemotherapeutic agents, and other drug classes. The hedgehog pathway inhibitors segment dominated the market with the largest revenue share of 42.4% in 2024.
 

• The growing incidence of basal cell carcinoma, especially in regions with high exposure to the sun and older populations, is enhancing the adoption of hedgehog pathway inhibitors due to the effectiveness in treating those affected.
   
• Important drugs in this category such as vismodegib (Erivedge, Roche) and sonidegib (Odomzo, Sun Pharmaceutical) are both effective for patients suffering from advanced and metastatic BCC. Vismodegib, the first FDA-approved hedgehog pathway inhibitor, has established a strong market precedent and sonidegib is useful to those patients who have more specific needs. The shift toward these therapies as opposed to the conventional options such as chemotherapy or radiation has greatly added to the market growth.
   
• Furthermore, research and clinical trials are already in progress and are likely to result in additional regulatory approvals of hedgehog pathway inhibitors for the treatment of other skin cancers or certain epitheliomas.
   
• For instance, Sol-Gel Technologies acquired the topical patidegib, a hedgehog signaling pathway inhibitor, from PellePharm for the treatment of Gorlin syndrome in January 2023. Patients with this condition have an abnormally high chance of acquiring basal cell skin cancer. It is believed that the overall market growth for the industry will increase due to an expanding range of therapies and increasing number of eligible patients.
   

Based on distribution channel, the epithelioma treatment market is segmented into hospital pharmacies, retail pharmacies, e-commerce, and other distribution channels. The hospital pharmacies segment dominated the market with the largest revenue of USD 2.7 billion in 2024.
 

• Hospital pharmacies are the primary contact points for the patients being admitted to hospitals for disease treatments. Further, there is a surge in the number of patient admissions for BCC and SCC in hospitals globally due to the increase in prevalence of these diseases. Thus, this segment also grows proportionally.
   
• Further, these pharmacies provide quick access to essential medications for patients requiring particular care.
   
• Additionally, hospital pharmacies are essential in delivering supportive care services, including pain management and symptom control, which are essential for patients receiving treatment for epitheliomas. This integrated approach helps improve patient outcomes and satisfaction.

North America: The U.S. epithelioma treatment market is projected to grow significantly, from USD 2 billion in 2023 to USD 4.7 billion by 2034.
 

• The country benefits from strong regulatory agencies such as U.S. FDA. The regulatory environment favors the adoption of novel therapies such as Hedgehog pathway inhibitors and immune checkpoint inhibitors.
   
• For instance, in March 2024, Elahere (mirvetuximab soravtansine-gynx) by AbbVie, was granted full FDA approval for use in adults with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.
   
• With these approvals, the country’s market growth is expected to progress in the near future.
   

Europe: The epithelioma treatment industry in UK is expected to experience significant and promising growth from 2025 to 2034.
 

• There has been a sharp rise in instances of skin cancer, especially basal and squamous skin cancer in the UK. For instance, the Cancer Research UK has stated that since early 1990s, the new cases of non-melanoma skin cancer (NMSC) in the UK have increased by 166%. It is estimated that by 2025, the country will have nearly 400,000 cases of this disease annually.
   
• Further, the rise has been caused by more exposure to the sun, a change in lifestyle habits, and aging population in the country.
   
• Therefore, the market for treatment of epithelioma in the UK is poised to grow significantly in coming years.
   

Asia Pacific: Japan epithelioma treatment market is anticipated to witness lucrative growth between 2025 – 2034.
 

• The regulatory bodies in the country such as the Pharmaceuticals and Medical Devices Agency (PMDA) and the Japanese Ministry of Health, Labor and Welfare (MHLW) support the development and approval of new therapies for cancer.
   
• For instance, in September of 2024, Merck reported that the HCLW of Japan approved KEYTRUDA (pembrolizumab) for use in Japan for newly diagnosed non-small cell lung cancer (NSCLC) as well as for radical unmethylated urothelial carcinoma. These innovative treatment strategies will improve patient outcomes due to the faster adoption of innovative solutions and hence will increase market growth in the country.
   

Middle East and Africa: Saudi Arabia epithelioma treatment industry is expected to experience significant and promising growth from 2025 to 2034.
 

• In Saudi Arabia, as the health insurance coverage expands, more individuals are gaining access to cancer treatment services. The Council of Health Insurance indicates that periodic examinations during the diagnosis and treatment of cancer are covered by insurance. The coverage made available is positively impacting the treatment rates for epitheliomas because patients are able to seek medical attention without paying high out-of-pocket costs.
   
• Additionally, the country receives support from public health campaigns, which is resulting in an increase in awareness regarding skin health. People are more willing to undergo dermatological consultations and skin examinations which is resulting in higher detection rates of epitheliomas, further supporting market growth.
   

Epithelioma Treatment Market Share

Roche, Bristol-Myers Squibb, Merck & Co., Novartis, and Regeneron Pharmaceuticals are the top 5 players in the market. These companies have captured revenue share of approximately 50% in the industry. The revenue share is maintained, and competitive advantage of these companies is sustained due to investment in innovative treatment methodologies including targeted therapy, cancer immunotherapy, and combination therapies. These treatment therapies, for instance, Roche’s Erivedge and Bristol-Myers Squibb’s Opdivo have showed strong efficacy in treating BCC and SCC, supporting their market position.
 

In addition, the mergers and acquisitions as well as partnerships and collaborations between companies to strengthen their oncology portfolios, is changing the competition dynamics of the market. For instance, Bristol-Myers Squibb's purchased Celgene in 2019 for USD 74 billion which helped the company to compete with other companies in the immuno-oncology and skin cancer treatment space in a better way. In addition, new entrants into the market are working on new approaches of immunotherapy in order to enhance effectiveness of treatments which deepens the rivalry.
 

Epithelioma Treatment Market Companies

Some of the eminent market participants operating in the epithelioma treatment industry include:

• Amgen
• AstraZeneca
• BeiGene
• Bristol-Myers Squibb
• F. Hoffmann-La Roche
• Johnson & Johnson
• Merck and Co.
• Novartis
• Pfizer
• Regeneron Pharmaceuticals
• Sanofi
• Sun Pharmaceutical Industries
   
• F. Hoffmann-La Roche is one of the leading players in the oncology market with a strong presence worldwide. For instance, Erivedge is the first FDA-approved Hedgehog pathway inhibitor for advanced basal cell carcinoma (BCC), demonstrating Roche’s leadership in the market.
   
• Merck’s Keytruda is one of the most widely used immunotherapies and has secured various approvals for different types of skin cancers. The company continues to expand Keytruda’s indications, ensuring a competitive edge in the market.
   

Epithelioma Treatment Industry News:

• In November 2024, AbbVie received European Commission (EC) approval for ELAHERE (mirvetuximab soravtansine), targeting adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who had undergone one to three prior systemic treatments. ELAHERE is the first folate receptor alpha (FR?)-directed antibody drug conjugate (ADC) approved in the European Union (EU), Iceland, Norway, Liechtenstein, and Northern Ireland. This approval is expected to drive market growth in the ovarian cancer treatment sector.
   
• In June 2021, Sanofi and Regeneron Pharmaceutical's PD-1 inhibitor Libtayo (cemiplimab) received approval from the European Commission (EC) as a first line of treatment in patients with advanced NSCLC. The tumor cells must have ≥50% PD-L1 expression with no EGFR, ALK or ROS1 aberrations. These patients should be having locally advanced NSCLC or metastatic NSCLC and they should not be a candidate for definitive chemoradiation. This approval enhanced the available treatment options for patients with advanced BCC and aided in market growth.
   

The epithelioma treatment market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Type

• Basal cell carcinoma
• Squamous cell carcinoma
• Other types

Market, By Drug Class

• Hedgehog pathway inhibitors
• Immune checkpoint inhibitors
• Chemotherapeutic agents
• Other drug classes

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• E-commerce
• Other distribution channels

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America 
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE